Evidence map›Paper›PMID 40283999›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Smart Drug Delivery Systems Based on Cyclodextrins and Chitosan for Cancer Therapy.

Larisa Păduraru, Alina-Diana Panainte, Cătălina-Anișoara Peptu, Mihai Apostu, Mădălina Vieriu, Tudor Bibire, Alexandru Sava, Nela Bibire

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Larisa PăduraruDepartment of Analytical Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy from Iasi, 16th Universitatii Street, 700116 Iasi, Romania.ORCID 0009-0004-7546-1992
Alina-Diana PanainteDepartment of Analytical Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy from Iasi, 16th Universitatii Street, 700116 Iasi, Romania.ORCID 0000-0001-5255-2737
Cătălina-Anișoara PeptuDepartment of Natural and Synthetic Polymers, Faculty of Chemical Engineering and Environmental Protection, "Gheorghe Asachi" Technical University of Iasi, 71st Prof. Dr. Docent Dimitrie Mangeron Street, 700050 Iasi, Romania.
Mihai ApostuDepartment of Analytical Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy from Iasi, 16th Universitatii Street, 700116 Iasi, Romania.ORCID 0000-0002-4107-9566
Mădălina VieriuDepartment of Analytical Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy from Iasi, 16th Universitatii Street, 700116 Iasi, Romania.ORCID 0000-0002-5379-3361
Tudor Bibire"St. Spiridon" County Clinical Emergency Hospital, 1st Independentei Blvd., 700111 Iasi, Romania.ORCID 0009-0001-8142-9778
Alexandru SavaDepartment of Analytical Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy from Iasi, 16th Universitatii Street, 700116 Iasi, Romania.ORCID 0000-0002-2759-4860
Nela BibireDepartment of Analytical Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy from Iasi, 16th Universitatii Street, 700116 Iasi, Romania.ORCID 0000-0003-3741-6184

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite improvements in therapeutic approaches like immunotherapy and gene therapy, cancer still remains a serious threat to world health due to its high incidence and mortality rates. Limitations of conventional therapy include suboptimal targeting, multidrug resistance, and systemic toxicity. A major challenge in current oncology therapies is the development of new delivery methods for antineoplastic drugs that act directly on target. One approach involves the complexation of antitumor drugs with cyclodextrins (CDs) and chitosan (CS) as an attempt to counteract their primary limitations: low water solubility and bioavailability, diminished in vitro and in vivo stability, and high dose-dependent toxicity. All those drawbacks may potentially exclude some therapeutic candidates from clinical trials, thus their integration into smart delivery systems or drug-targeting technologies must be implemented. We intended to overview new drug delivery systems based on chitosan or cyclodextrins with regard to the current diagnosis and cancer management. This narrative review encompasses full-length articles published in English between 2019 and 2025 (including online ahead of print versions) in PubMed-indexed journals, focusing on recent research on the encapsulation of diverse antitumor drugs within those nanosystems that exhibit responsiveness to various stimuli such as pH, redox potential, and folate receptor levels, thereby enhancing the release of bioactive compounds at tumor sites. The majority of the cited references focus on the most notable research, studies of novel applications, and scientific advancements in the field of nanostructures and functional materials employed in oncological therapies over the last six years. Certainly, there are additional stimuli with research potential that can facilitate the drug's release upon activation, such as reactive oxygen species (ROS), various enzymes, ATP level, or hypoxia; however, our review exclusively addresses the aforementioned stimuli presented in a comprehensive manner.

Indexed as

anticancerbiopolymerschitosancyclodextrinsdrug deliveryfolate receptorsglutathionenanoparticles

Identifiers

PMID40283999
PMCPMC12030441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.